<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9785">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05690243</url>
  </required_header>
  <id_info>
    <org_study_id>170</org_study_id>
    <nct_id>NCT05690243</nct_id>
  </id_info>
  <brief_title>Minds Navigating the Diagnosis of Mild Cognitive Impairment</brief_title>
  <acronym>MIND-MCI</acronym>
  <official_title>Minds Navigating the Diagnosis of Mild Cognitive Impairment (MiND-MCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tuscaloosa Research &amp; Education Advancement Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Tuscaloosa Research &amp; Education Advancement Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to find out if a 9 week group therapy using video from&#xD;
      home will help veterans with Mild Cognitive Impairment (MCI). The main questions it aims to&#xD;
      answer are:&#xD;
&#xD;
        -  is the video therapy user-friendly for veterans?&#xD;
&#xD;
        -  does it improve veterans well-being and quality-of-life?&#xD;
&#xD;
      Veterans will be asked to attend nine 1 hour small group video sessions and will complete&#xD;
      questionnaires before and after the sessions.&#xD;
&#xD;
      Researchers will compare the group of veterans that starts the video sessions right away with&#xD;
      a group that waits before starting the video sessions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be achieved by conducting a two-arm, single-blind, pilot randomized controlled&#xD;
      trial at two VA medical centers. Eighty participants at each site will be randomized in a 1:1&#xD;
      ratio to either the MiND-MCI group or waitlist control group. Participants will be Veterans&#xD;
      ages 60 and older with a diagnosis of MCI, at least one cardiovascular risk factor,&#xD;
      self-reported cognitive complaint, and self-reported difficulty adjusting to MCI diagnosis or&#xD;
      symptoms. MiND-MCI will be delivered in nine weekly 60-minute sessions via telehealth in&#xD;
      groups of 5 to 7 Veterans. Feasibility and acceptability process data will be tracked&#xD;
      throughout the study. Acceptability measures pertaining to participants' perceptions of&#xD;
      MiND-MCI will be collected at post-treatment using quantitative and qualitative assessment&#xD;
      methods. Outcome measures collected at baseline, post-treatment, and 12-week follow-up will&#xD;
      assess global QoL, MCI-related QoL, MCI-related self-efficacy, depression, anxiety,&#xD;
      loneliness, coping, and cognitive functioning.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2023</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two-arm, single-blind, pilot randomized controlled trial with 1:1 randomization. Wait List Control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Assessor and fidelity monitor will be blinded to treatment group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of a group video-telehealth intervention for veterans with MCI</measure>
    <time_frame>At Week 0 (randomization)</time_frame>
    <description>percentage of screened, eligible subjects that enroll in intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of a group video-telehealth intervention for veterans with MCI</measure>
    <time_frame>At Week 10 (one week after completion of the 9 video-telehealth sessions)</time_frame>
    <description>percentage of subjects that attend 70% or more of scheduled sessions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Quality of Life in Alzheimers Disease (QOL-AD, range of 13-52) scale in Veterans with Mild Cognitive Impairment following participation in a 9-week video-telehealth intervention.</measure>
    <time_frame>baseline to 12 week post-treatment follow-up visit</time_frame>
    <description>change in the Quality of Life in Alzheimers Disease (QOL-AD) Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cognitive Dysfunction</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Group therapy delivered via video telehealth</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nine sessions of 60 min each group therapy delivered via telehealth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group therapy delivered via video telehealth - wait list control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nine sessions of 60 min each group therapy delivered via telehealth after a waiting period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Group psychotherapy delivered via video telehealth</intervention_name>
    <description>Small group psychotherapy using psychoeducation and skills training aimed at addressing modifiable factors in MCI.</description>
    <arm_group_label>Group therapy delivered via video telehealth</arm_group_label>
    <arm_group_label>Group therapy delivered via video telehealth - wait list control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Veteran&#xD;
&#xD;
          -  age 60 or older&#xD;
&#xD;
          -  diagnosis of MCI, diagnosed at least a month or longer prior to screening&#xD;
&#xD;
          -  diagnosis of at least one cardiovascular risk factor (i.e., hypertension, diabetes&#xD;
             mellitus II, hyperlipidemia/hypercholesterolemia, or obesity)&#xD;
&#xD;
          -  self-reported cognitive complaint (i.e., &quot;Do you have problems with your memory or&#xD;
             thinking abilities?&quot;)&#xD;
&#xD;
          -  self-reported difficulty adjusting to declines in cognitive functioning (i.e., &quot;Have&#xD;
             these problems with memory or thinking impacted you, your life, or others in your&#xD;
             life?&quot;)&#xD;
&#xD;
          -  English speaking, and (h) ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnosis of dementia or a neurodegenerative disorder&#xD;
&#xD;
          -  diagnosis of serious mental illness likely to impact cognition (i.e., schizophrenia or&#xD;
             bipolar I disorder)&#xD;
&#xD;
          -  acutely suicidal or homicidal&#xD;
&#xD;
          -  actively psychotic&#xD;
&#xD;
          -  active substance use disorder&#xD;
&#xD;
          -  limited life expectancy due to a terminal medical condition&#xD;
&#xD;
          -  receiving ongoing chemotherapy or radiation treatment at time of screening&#xD;
&#xD;
          -  residing in an assisted living or residential care facility&#xD;
&#xD;
          -  currently participating in another psychotherapy, health promotion intervention, or&#xD;
             cognitive training program, and&#xD;
&#xD;
          -  any significant changes to psychotropic medications or medications for memory and&#xD;
             cognition in the past month. Participants prescribed psychotropic medications and&#xD;
             medications for memory and cognition will be asked to stay on their current dosages&#xD;
             for the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Pilkinton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tuscaloosa Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lindsay Jacobs, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tuscaloosa Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Pilkinton, MD</last_name>
    <phone>205-554-20944</phone>
    <email>patricia.pilkinton@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lindsay Jacobs, PhD</last_name>
    <phone>205-554-2337</phone>
    <email>jacob008@ua.edu</email>
  </overall_contact_backup>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 21, 2022</study_first_submitted>
  <study_first_submitted_qc>January 9, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>January 9, 2023</last_update_submitted>
  <last_update_submitted_qc>January 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tuscaloosa Research &amp; Education Advancement Corporation</investigator_affiliation>
    <investigator_full_name>Lori Davis, MD</investigator_full_name>
    <investigator_title>Associate Chief of Staff, Research Service, Tuscaloosa Veterans Affairs Medical Center</investigator_title>
  </responsible_party>
  <keyword>therapy</keyword>
  <keyword>video telehealth</keyword>
  <keyword>veteran</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

